Generex has published the results from preclinical studies, demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine.
The immunotherapeutic vaccine for HPV-induced cancers make use of the Ii-Key platform technology developed by scientists at Antigen, Generex’s wholly-owned immunotherapeutics subsidiary.
The Antigen Express studies demonstrated that mice immunized with an Ii-Key/HPV16 E7 hybrid showed increased killing of cells expressing an HPV-specific antigen, but not control cells lacking the antigen.
Consistent with the predicted mechanism of action of the vaccine, HPV-specific activation of CD4+T helper cells was observed in immunized mice.
The current studies demonstrate an additional application of the Ii-Key technology platform being developed at Antigen Express. Currently, another peptide designed with this technology is the subject of three clinical trials – a phase II trial in breast cancer patients, a phase I trial in prostate cancer patients, and a separate phase I trial in breast or ovarian cancer patients, wherein it is being tested in combination with another peptide vaccine.